Pushing Pipelines Forward for Long-Term Success - Research Report on Vertex, Santarus, Arena Pharmaceuticals, Seattle Genetics and Nektar Therapeutics

NEW YORK, March 8, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Santarus, Inc. (NASDAQ: SNTS), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Seattle Genetics, Inc. (NASDAQ: SGEN) and Nektar Therapeutics (NASDAQ: NKTR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Vertex Pharmaceuticals Incorporated Research Report

Vertex Pharmaceuticals recently revealed data from its Phase 2 influenza challenge study, saying that its investigational medicine VX-787 was able to reduce viral shedding by 94 percent versus placebo. There was also a statistically significant reduction in the severity and duration of influenza-like symptoms for patients that were given the highest dosage. These successful results bring Vertex closer to completing the development of a drug that directly inhibits replication of influenza A, including H1 and H5 influenza strains. Aside from this, Vertex is also developing treatments for cystic fibrosis, hepatitis c and autoimmune diseases. With a clear business strategy and productive R&D programs, Vertex is on its way to significant growth. The Full Research Report on Vertex Pharmaceuticals Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/59ce_VRTX]

--

Santarus, Inc. Research Report

Santarus is starting the year strong after the FDA approved UCERIS, its treatment for patients with active, mild to moderate ulcerative colitis. It also re-launched its ZEGERID drug weeks ago. Last year, the company was able to advance its pipeline, reporting positive Phase III results for a couple of its drugs including RUCONEST, its treatment for hereditary angioedema. It also reported record annual record revenue of $218 million. With commercial success for its products as well as a string of approvals from the FDA, Santarus is poised for another year of excellent results. The Full Research Report on Santarus, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/7f82_SNTS]

--

Arena Pharmaceuticals, Inc. Research Report

Arena Pharmaceuticals recently reported its fourth quarter and full year 2012 results, with 27.6 million for the full year compared to $12.7 million in 2011. Furthermore, the FDA recently approved the company's first drug, BELVIQ, a weight loss and weight management drug for obese and overweight patients. BELVIQ will be available by prescription in the United States and it has also been filed for approval to the Korea Food and Drug Administration. Aside from this, Arena Pharmaceuticals has a treatment for pulmonary arterial hypertension in development. By expanding to new markets and by advancing its pipeline, Arena Pharmaceuticals is positioning itself for long-term growth. The Full Research Report on Arena Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/3996_ARNA]

--

Seattle Genetics, Inc. Research Report

Seattle Genetics is currently in the process of bringing its lymphatic disease drug ADCETRIS to commercial success. Last year, the company reported ADCETRIS net product sales of $35.4 million in the fourth quarter and $138.2 million for the entire year. Going forward, the company has 20 ADCETRIS clinical trials to broadly explore its therapeutic potential. The company also expects to submit an investigational new drug application to the FDA for a number of drugs, including one for myeloid leukemia and breast cancer. With a strong financial position and cash flow from product sales, the company is set to fulfill these goals. The Full Research Report on Seattle Genetics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/e97f_SGEN]

--

Nektar Therapeutics Research Report

Nektar Therapeutics is confident about the coming year, with five late-stage programs tackling multiple therapeutic areas. Furthermore, Nektar Therapeutics' partner in developing naloxegol, AstraZeneca, is preparing to submit registrations filings in the US and EU in the third quarter this year. It also has programs for pneumonia and a potential breakthrough for the treatment of chronic pain. Recognizing Nektar Therapeutics' potential, Deutsche Bank raised its price target for shares of Nektar Therapeutics to $13, and reiterated its Buy rating on the stock. Analysts at Deutsche Bank note the company's cash balance of $302 million, which may be "more than enough to allow the company to reach its key milestones." The Full Research Report on Nektar Therapeutics - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/62a3_NKTR]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.

Contact: Patricia Byers
Email: [email protected]
Main: +1-480-745-7826

SOURCE Investors-Alliance